MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$16,380,840
Interest income
$1,461,079
Loss from operations
-$17,841,919
Total costs and
expenses
$17,841,919
Change in fair value
contingent consideration
$373,354
Research and development
$10,839,150
Selling, general and
administrative
$7,376,123
Back
Back
Income Statement
source: myfinsight.com
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)